341. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial.
作者: Michael Haude.;Hüseyin Ince.;Alexandre Abizaid.;Ralph Toelg.;Pedro Alves Lemos.;Clemens von Birgelen.;Evald Høj Christiansen.;William Wijns.;Franz-Josef Neumann.;Christoph Kaiser.;Eric Eeckhout.;Soo Teik Lim.;Javier Escaned.;Hector M Garcia-Garcia.;Ron Waksman.
来源: Lancet. 2016年387卷10013期31-9页
Absorbable scaffolds were designed to overcome the limitations of conventional, non-absorbable metal-based drug-eluting stents. So far, only polymeric absorbable scaffolds are commercially available. We aimed to assess the safety and performance of a novel second-generation drug-eluting absorbable metal scaffold (DREAMS 2G) in patients with de-novo coronary artery lesions.
342. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
作者: Steven W Lockley.;Marlene A Dressman.;Louis Licamele.;Changfu Xiao.;Dennis M Fisher.;Erin E Flynn-Evans.;Joseph T Hull.;Rosarelis Torres.;Christian Lavedan.;Mihael H Polymeropoulos.
来源: Lancet. 2015年386卷10005期1754-64页
Most totally blind people have non-24-hour sleep-wake disorder (non-24), a rare circadian rhythm disorder caused by an inability of light to reset their circadian pacemaker. In two consecutive placebo-controlled trials (SET and RESET), we assessed safety and efficacy (in terms of circadian entrainment and maintenance) of once-daily tasimelteon, a novel dual-melatonin receptor agonist.
345. Achieving best outcomes for patients with cardiovascular disease in China by enhancing the quality of medical care and establishing a learning health-care system.
作者: Lixin Jiang.;Harlan M Krumholz.;Xi Li.;Jing Li.;Shengshou Hu.
来源: Lancet. 2015年386卷10002期1493-505页
China has an immediate need to address the rapidly growing population with cardiovascular disease events and the increasing number of people living with this illness. Despite progress in increasing access to services, China faces the dual challenge of addressing gaps in quality of care and producing more evidence to support clinical practice. In this Review, we address opportunities to strengthen performance measurement, programmes to improve quality of care, and national capacity to produce high-impact knowledge for clinical practice. Moreover, we propose recommendations, with implications for other diseases, for how China can immediately make use of its Hospital Quality-Monitoring System and other existing national platforms to assess and improve performance of medical care, and to generate new knowledge to inform clinical decisions and national policies.
346. Consolidating the social health insurance schemes in China: towards an equitable and efficient health system.
Fragmentation in social health insurance schemes is an important factor for inequitable access to health care and financial protection for people covered by different health insurance schemes in China. To fulfil its commitment of universal health coverage by 2020, the Chinese Government needs to prioritise addressing this issue. After analysing the situation of fragmentation, this Review summarises efforts to consolidate health insurance schemes both in China and internationally. Rural migrants, elderly people, and those with non-communicable diseases in China will greatly benefit from consolidation of the existing health insurance schemes with extended funding pools, thereby narrowing the disparities among health insurance schemes in fund level and benefit package. Political commitments, institutional innovations, and a feasible implementation plan are the major elements needed for success in consolidation. Achievement of universal health coverage in China needs systemic strategies including consolidation of the social health insurance schemes.
347. Acute kidney injury in China: a cross-sectional survey.
作者: Li Yang.;Guolan Xing.;Li Wang.;Yonggui Wu.;Suhua Li.;Gang Xu.;Qiang He.;Jianghua Chen.;Menghua Chen.;Xiaohua Liu.;Zaizhi Zhu.;Lin Yang.;Xiyan Lian.;Feng Ding.;Yun Li.;Huamin Wang.;Jianqin Wang.;Rong Wang.;Changlin Mei.;Jixian Xu.;Rongshan Li.;Juan Cao.;Liang Zhang.;Yan Wang.;Jinhua Xu.;Beiyan Bao.;Bicheng Liu.;Hongyu Chen.;Shaomei Li.;Yan Zha.;Qiong Luo.;Dongcheng Chen.;Yulan Shen.;Yunhua Liao.;Zhengrong Zhang.;Xianqiu Wang.;Kun Zhang.;Luojin Liu.;Peiju Mao.;Chunxiang Guo.;Jiangang Li.;Zhenfu Wang.;Shoujun Bai.;Shuangjie Shi.;Yafang Wang.;Jinwei Wang.;Zhangsuo Liu.;Fang Wang.;Dandan Huang.;Shun Wang.;Shuwang Ge.;Quanquan Shen.;Ping Zhang.;Lihua Wu.;Miao Pan.;Xiting Zou.;Ping Zhu.;Jintao Zhao.;Minjie Zhou.;Lin Yang.;Wenping Hu.;Jing Wang.;Bing Liu.;Tong Zhang.;Jianxin Han.;Tao Wen.;Minghui Zhao.;Haiyan Wang.; .
来源: Lancet. 2015年386卷10002期1465-71页
Acute kidney injury (AKI) has become a worldwide public health problem, but little information is available about the disease burden in China. We aimed to evaluate the burden of AKI and assess the availability of diagnosis and treatment in China.
348. Contrasting male and female trends in tobacco-attributed mortality in China: evidence from successive nationwide prospective cohort studies.
作者: Zhengming Chen.;Richard Peto.;Maigeng Zhou.;Andri Iona.;Margaret Smith.;Ling Yang.;Yu Guo.;Yiping Chen.;Zheng Bian.;Garry Lancaster.;Paul Sherliker.;Shutao Pang.;Hao Wang.;Hua Su.;Ming Wu.;Xianping Wu.;Junshi Chen.;Rory Collins.;Liming Li.; .
来源: Lancet. 2015年386卷10002期1447-56页
Chinese men now smoke more than a third of the world's cigarettes, following a large increase in urban then rural usage. Conversely, Chinese women now smoke far less than in previous generations. We assess the oppositely changing effects of tobacco on male and female mortality.
|